Current Neuro-Oncology
Volume
28 Number 16
10 June 2026
Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 16, 10 June
Gentner B, Eoli M, Farina F, Barcella M, Capotondo A, Mazzoleni S,
Brambilla V, Francavilla A, Garramone M, Carrabba MG, Ferla V,
Bruno A, Alvisi G, Coltella N, Montini E, Hadadi L, Capt C,
Cuccarini V, Bruzzone MG, Di Meco F, Legnani FG, Ferroli P, Acerbi
F, Pallini R, D'Alessandris QG, Olivi A, Gagliardi F, Snider S,
Mortini P, Patanè M, Fiocchi A, Berno V, Poliani PL,
Finocchiaro G, Russo C, Ciceri F, Naldini L.
Tumor-targeted
interferon-α gene therapy for glioblastoma: a phase 1 trial.
Nat
Med. 2026 Jun 1;32(6):2216-2226. doi:
10.1038/s41591-026-04419-1. PMID:
42225991. Trial
registration ID: NCT03866109˰
ˍ
Badran
K, Robinson D, Ali A, Dherijha M.
Outcomes
in spinal ependymoma: A retrospective analysis of 38 patients.
Surg
Neurol Int.
2026 Jun 5;17:344. doi:
10.25259/SNI_1003_2025. PMID:
42404445. ˍ
Himic V, Johnson ML, Ratnaparkhi A, Mayrand RC, Chandar J,
Govindarajan V, Kreatsoulas DC, Jahangiri A, Gersey ZC, Aaronson
DM, Komotar RJ, Ivan ME, Shah AH.
Butterfly
gliomas: to biopsy or to ablate - a longitudinal cohort study.
J
Neurooncol. 2026 Jun 5;178(2):44. doi:
10.1007/s11060-026-05655-8. PMID:
42243447. ˍ
Oxman
L, Laviv Y.
Long-term
survival in glioblastoma patients treated with dopamine agonists:
A report of two cases and implications for drug repurposing.
Surg
Neurol Int.
2026 Jun 5;17:340. doi:
10.25259/SNI_243_2026. PMID:
42404464. ˍ
Connelly
JM, Zoss CJ, Szabo A, Mirza SP, Adom F, Bernstein LR, Al-Gizawiy
MM, Schmainda KM, Chitambar CR.
A
phase 1 trial of iron metabolism-targeting oral gallium maltolate
in recurrent and refractory glioblastoma.
Neurooncol
Adv.
2026 Jun 8;8(1):vdag154. doi:
10.1093/noajnl/vdag154. PMID:
42333305. Trial
registration ID:
NCT04319276. ˍ
Gurlek
Tumer E, Tuysuz S, Yetisgin E, Guney Y.
Long-Term
Survival in IDH-Wild-Type Glioblastoma: Clinical and Molecular
Insights From Two Exceptional Cases.
Cureus.
2026 Jun 8;18(6):e110449. doi:
10.7759/cureus.110449. PMID:
42422637. ˍ
Munlapudi
V, Guzzino J, Crompton DJ, Agarwal S, Lehrer EJ, Kern S, Bogan A,
Vora SA, Quinones-Hinojosa A, Burns TC, Sherman WJ, Brown PD,
Laack N, Peterson J, Uhm JH, Ruff MW, Sener UT, Breen WG,
Trifiletti DM.
Defining
rapid early progression in glioblastoma-A volumetric approach.
Neurooncol
Adv.
2026 Jun 8;8(1):vdag153. doi:
10.1093/noajnl/vdag153. PMID:
42382820. ˍ
Lucas
A, Peereboom D, Rauf Y, Li H, Hanlon J, Ahluwalia M.
Phase
2 study of regorafenib in patients with progressive glioblastoma
after failure of bevacizumab.
Neurooncol
Adv.
2026 Jun 9;8(1):vdag144. doi:
10.1093/noajnl/vdag144. PMID:
42325608. Trial
registration ID:
NCT04051606.
ˍ
Park S, Kim D, Yoon HI, Lee JH, Lim DH, Kim N, Song JH, Suh CO,
Wee CW, Kim IA.
Optimal clinicogenetic
criteria for post-operative re-irradiation in recurrent
glioblastoma: KROG 21-02.
ESMO
Open. 2026 Jun 9;11(6):107730. doi:
10.1016/j.esmoop.2026.107730. PMID:
42258967. ˍ
Parker M, Carmichael A, Lucas CG Jr, Schreck KC, Redmond KJ,
Kleinberg LR, Rincon-Torroella J.
Survival
after hypofractionated radiation versus standard radiation in
glioblastoma by MGMT promoter methylation status and age: an
analysis of the national cancer database.
J
Neurooncol. 2026 Jun 9;178(2):55. doi:
10.1007/s11060-026-05612-5. PMID:
42265433˰ ˍ
Breese J, Lloyd W, Fothergill A, Djoukhadar I, Tyler A, Bullock E,
Cloran K, Li K, Zhu X, Alfaifi B, Sereno T, Naveen Golchha P,
McMahon A, Karabatsou K, D'Urso P, Maye H, Bailey M, Hannan C,
King AT, Jackson A, Hinz R, Lewis D, Coope D.
USPIO
enhanced MR imaging in CNS tumors (UMIC): a study protocol.
Nanomedicine
(Lond). 2026 Jun 10;21(12):1713-1721. doi:
10.1080/17435889.2026.2681555. PMID:
42267547. Trial
registration ID: NCT06572475. ˍ
Gan HK, Cher L, Inglis PL, Lwin Z, Gunjur A, Balasubramanian A,
Schmidt A, Wichmann CW, Guo N, Lee ST, Thomas P, Scott FE, Shard
C, Fluck K, Coombs N, Palmer J, Vail ME, Allen S, Patil A, Pal B,
O'Keefe GJ, Gong SJ, Ninatti G, Day BW, Gomez GA, Janes PW, Scott
AM.
A Phase 1 and Biodistribution
study of Ifabotuzumab, a humanized agonistic EphA3-targeted
antibody, in patients with recurrent glioblastoma.
Clin
Cancer Res. 2026 Jun 10. doi:
10.1158/1078-0432.CCR-25-3608. PMID:
42268288. Trial registration ID:
NCT00749638(?)˰ ˍ